Kay Hoong Chow - Concepedia

Author

Kay Hoong Chow

Eli Lilly (United States)

Also Known As

K. Chow, K.H. Chow, Kay Chow, Kay H. Chow, Kay Hoong Chow

Publications

425

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Eli Lilly (United Kingdom)The University of Texas MD Anderson Cancer Center Eli Lilly (Singapore)

About

Kay Hoong Chow is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	157
2	Health Sciences	2	2	87
3	Diabetes	1	1	23
4	Neurology	1	1	64
5	Nutrition	1	1	65

Kay Hoong Chow

Publications

409

Citations

H-Index

Page 1

	Year	Citations
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia David A. Rizzieri, Sarah Cooley, Olatoyosi Odenike, Leukemia & lymphoma/Leukemia and lymphoma	2016	74
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin Jhanelle E. Gray, Jeffrey R. Infante, Les Brail, Investigational New Drugs Molecular PharmacologyIntravenous Ly2090314Glycogen SynthaseFirst-in-human PhaseMedicine	2015	70
Using fish gelatin and pectin to make a low-fat spread Lai‐Hoong Cheng, Bock-Gu Lim, Kay Hoong Chow, Food Hydrocolloids Fish GelatinNutrition	2007	65
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Clinical Pharmacology & Therapeutics Geriatric PsychiatryNeurochemical BiomarkersPharmacotherapyAmyloid Plaque ClearanceAlzheimer's Disease	2023	64
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung, Clinical Cancer Research	2020	45
Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low Circulating Metabolite Exposure Maciej J. Zamek‐Gliszczynski, Trent L. Abraham, Jeffrey J. Alberts, Drug Metabolism and Disposition	2013	39
Do triglycerides modulate the effectiveness of clozapine? Saket Pande, Ric M. Procyshyn, M. Nazerali, International Clinical Psychopharmacology ObesityMetabolic SyndromeObserved Clinical ResponseBody CompositionClinical Response	2002	23
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Alzheimer s & Dementia Translational Research & Clinical Interventions	2023	19
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors Robert M. Jotte, Daniel D. Von Hoff, Fadi Braiteh, Investigational New Drugs	2014	10

Page 1